Capital International Sarl Sells 10,350 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Capital International Sarl lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 119,352 shares of the biopharmaceutical company’s stock after selling 10,350 shares during the period. Capital International Sarl’s holdings in Alnylam Pharmaceuticals were worth $47,460,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. First Horizon Corp increased its holdings in shares of Alnylam Pharmaceuticals by 20.7% during the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 28 shares during the period. Yousif Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 1.8% during the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after purchasing an additional 29 shares during the period. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 15.6% during the 3rd quarter. Bessemer Group Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 30 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares during the period. Finally, Everpar Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 6.3% during the 4th quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 37 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several research reports. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Chardan Capital restated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. Finally, Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 7,740 shares of company stock worth $2,420,214. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $303.05 on Friday. The stock has a market cap of $40.46 billion, a P/E ratio of 82.80 and a beta of 0.29. The company’s 50-day simple moving average is $307.66 and its 200 day simple moving average is $349.36. Alnylam Pharmaceuticals, Inc. has a twelve month low of $283.10 and a twelve month high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.